Funding for this research was provided by:
Institut National Du Cancer (CLIP2)
Received: 28 July 2022
Accepted: 5 September 2022
First Online: 21 October 2022
: This study was approved by the Comité de Protection des Personnes (CPP) Sud-Ouest et Outre Mer III (Bordeaux, France) according to good clinical practices and applicable laws and regulations. All methods were performed in accordance with the relevant guidelines and regulations. All patients provided written informed consent.
: The article does not contain any individual person’s data.
: AI: Research grant (AstraZeneca, Bayer, BMS, Merck, MSD, Pharmamar). The other authors declare that they have no competing interests.